CANNABIS
Nabiximols improves multiple sclerosis spasticity compared to placebo over 12 weeks
Eur J Neurol. 2011 Sep;18(9):1122-31. doi: 10.1111/j.1468-1331.2010.03328.x241 known responders to nabiximols treatment with multiple sclerosis received nabiximols (2.7 mg THC and 2.5 mg CBD per 100-uL actuation) treatment for 4 weeks, and were then randomized to receive either titrated doses of nabiximols or placebo through an oralmucosal spray over 12 weeks. The purpose of the study was to determine whether Nabiximols is associated with significantly better spasticity numeric rating scores (NRS), spasm frequency, sleep disruptions, and quality of life compared to placebo. Results indicate that Nabiximols significantly better improvements in mean spasticity NRS scores, spasm frequency, sleep disruption and several quality of life measures compared to placebo, while maintaining a similar rate of adverse events.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
